NOT FOR RELEASE, PUBLICATION, OR
DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Integrated Diagnostics Holdings plc
Completion of EGX
Delisting
5 September 2024
Integrated Diagnostics Holdings plc
("IDH" or the "Company") refers to:
(i) the
shareholder resolutions passed at the Company's Extraordinary
General Meetings held on 12 June 2024 and 18 July 2024 approving,
amongst other things, the voluntary delisting (the "EGX Delisting") of the Company's
ordinary shares (the "Shares") from the Egyptian Exchange
(the "EGX") and the
Company's repurchase of Shares from the beneficial owners of the
Shares that were traded on the EGX and held by Misr for Central
Clearing, Depository and Registry ("MCDR") ("EGX Shares") if
so required by such beneficial owners during the relevant
period;
(ii) the
Company's announcement on 13 August 2024 in relation to the
timeline for the share buyback under the EGX's special operations
market (OPR); and
(iii) the
Company's announcement on 27 August 2024 in relation to the share
buyback under the EGX's special operations market (OPR).
Further to the Company's repurchase
of 18,673,728 EGX Shares on 26 August 2024 pursuant to the share
buyback under the EGX's special operations market (OPR), the EGX's
Listing Committee has, on 4 September 2024, published its formal
decision to delist the Shares from the EGX. As a result, the
Company's listing information has been removed from the EGX's
database, effective as at the commencement of the trading session
on 5 September 2024.
Accordingly, the EGX Delisting has
become effective and completed on 4 September 2024, and the last
trading date of the Shares on the EGX was 4 September
2024.
The Shares remain
admitted to the equity shares (transition)
category (previously, the standard listing segment) of the Official
List of the UK Financial Conduct Authority and admitted to trading
on the main market for listed securities of the London Stock
Exchange (the "LSE"), which
is now the sole listing venue of the Company.
Following the completion of the EGX
Delisting, all remaining EGX Shares that were not validly tendered
into the EGX's special operations market (OPR) and repurchased by
the Company pursuant to the share buyback are no longer capable of
being traded on the EGX (such EGX Shares, the "Remaining Shares").
As set out in the Company's circular
dated 1 July 2024, the Company will, in accordance with the
Company's Articles of Association and the laws of Jersey, take such
steps as are necessary to ensure that the Remaining Shares are no
longer held by MCDR, and instead are held directly by the relevant
underlying beneficial owners (the "Remaining Shareholders") as set out in
the register maintained by MCDR as at the date of completion of the
EGX Delisting. These steps include, amongst other things, making
the relevant entries in the Company's register of members to
reflect the Remaining Shareholders as the holders of their
respective Remaining Shares in place of MCDR, and issuing and
despatching share certificates to the Remaining Shareholders in
respect of their respective holdings of Remaining
Shares.
Thereafter, a Remaining Shareholder
can, should they so wish, elect at their own cost to engage a
broker with CREST facilities to dematerialise and hold their
Remaining Shares in a form that allows such Shares to be traded on
the main market for listed securities of the LSE via CREST (subject
to all required steps having been taken, including onboarding by
and engagement of such broker, and subject to all applicable rules
and procedures of CREST and the LSE).
Remaining Shareholders are required
to come to their own decisions in respect of their Remaining Shares
and, if in any doubt about the contents of this announcement or
what action should be taken, they are recommended to seek their own
personal financial, legal or tax advice from a stockbroker, legal,
tax or other appropriately authorised independent financial
adviser on the possible and recommended actions to be taken in
respect of their Remaining Shares. Please note that the Company cannot provide, and is not
purporting to provide, any financial, legal or tax advice in
relation to the possible actions that could be taken in respect of
the Remaining Shares.
For further information please
contact:
Integrated Diagnostics Holdings
plc
Tarek Yehia
Investor Relations
Director
T: +20 (0)2 3332 1126 | M: +20 10
6882 6678 | tarek.yehia@idhcorp.com
Company Secretary
Company Matters
IDHLondon@linkgroup.co.uk
-Ends-
About Integrated Diagnostics
Holdings (IDH)
IDH is a leading diagnostics
services provider in the Middle East and Africa offering a broad
range of clinical pathology and radiology tests to patients in Egypt,
Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core brands include Al Borg, Al
Borg Scan and Al Mokhtabar in Egypt, as well as Biolab
(Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan
(both in Sudan), and Biolab KSA (Saudi Arabia).
With over 40 years of experience, a long track record for quality
and safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of
over 3 ,000
diagnostics tests. From its base of 601 branches as of 31
December 2023, IDH
served over 8. 5 million
patients and performed more than 36.1 million tests in 2023. IDH will continue to add
laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group targets expansion in appealing markets,
including acquisitions in the Middle Eastern, African, and
East Asian markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH is a Jersey-registered
entity whose Shares are admitted to the equity shares (transition)
category (previously, the standard listing segment) of the Official
List of the UK Financial Conduct Authority and admitted to trading
on the main market for listed securities of the London Stock
Exchange since May 2015 (ticker: IDHC).
Learn more at idhcorp.com.
